| Name | Title | Contact Details |
|---|
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.
Balance Autism is a leading autism service organization in Iowa.
Qserve is your MedTech Partner for Regulatory & Quality Affairs and Clinical Trials. Need regulatory advice, support or training? Contact us.